Jamie Hayden via Crowdrise
January 11, 2013
BENEFITING: CYSTIC FIBROSIS FOUNDATION (inactive)
ORGANIZER: CYSTIC FIBROSIS FOUNDATION (inactive)
EVENT DATE: May 05, 2013
I am participating in my FIRST 5K this year with the Pittsburgh Marathon on May 4, 2013. This is a big challenge for me, but not as much of a challenge as a patient with cystic fibrosis. Not only am I running my first 5K, but I am raising money for the Cystic Fibrosis Foundation.
Cystic fibrosis is an inherited chronic disease that affects the lungs and digestive system of about 30,000 children and adults in the United States (70,000 worldwide). A defective gene and its protein product cause the body to produce unusually thick, sticky mucus that:
- clogs the lungs and leads to life-threatening lung infections;
- obstructs the pancreas and stops natural enzymes from helping the body break down and absorb food.
People take life for granted all the time, even the basic functions of life. CF patients look normal like everyone else, but every day is a challenge for them. They take numerous medications and beathing treatments daily. There are more than 30,000 reasons I am running for the Cystic Fibrosis Foundation, but here are at least 12 of them......
Amelia Dunbar, Age 1 - Bradfordwoods, PA
Alex Braun, Age 6 - Wexford, PA
Katie Gomes, Age 15 - North Hills, PA
Quinn Anlauf, Age 12 - North Huntingdon, PA
Rachel Kinney, Age 18 - Peters Twp., PA
Sofia Martin, Age 5 - McMurray, PA
Sam Underwood, Age 11 - Pittsburgh, PA
RJ Thompson, Age 27 - North Hills, PA
Emma Chichilla, Age 9 - Trafford, PA
Sydney Willig, Age 9 - North Huntingdon, PA
Brayden Freund, Age 5 - Coraoplis, PA (Brayden on the right with his older brother Shay)
Anthony Sarkis, Age 5 - North Huntingdon, PA (Brett Keisel, Anthony Sarkis, and his brother Matthew)
ANY donation helps, or join me in running for Team CF by clicking on "Charity Registration".
Breaking News for the Cystic Fibrosis Foundation!
In January 2012, the FDA approved Kalydeco, a new oral medication for the treatment of cystic fibrosis. About 4 percent of the CF population in the United States — will benefit directly from the drug.
Kalydeco has demonstrated it can markedly improve lung function, lower sweat chloride levels and help patients gain weight.
It marks a breakthrough in CF treatment because it is the first drug to address the underlying cause of the disease. Now is the time to save the other 96 percent of patients!